ABP-450, a botulinum toxin type A complex agent, failed to meet either primary or secondary end points in a cohort of 325 patients with chronic migraine.

Catch up on any of the neurology news headlines you may have missed over the course of April 2024, compiled all into one place by the NeurologyLive® team.

Jacqueline A. French, MD, professor of neurology at NYU Grossman School of Medicine, provided comments on a recently published study explaining the issues with diagnosing epilepsy in emergency department settings.

Clinical trials assessing cell therapies for Parkinson disease treatment may show early potential in improving both motor and nonmotor symptoms.

Treatment with SAGE-324/BIIB124 for essential tremor resulted in adverse events that included somnolence, dizziness, fatigue, and balance disorder.

Findings from a recent study suggest that the presence of negative myoclonus may serve as a diagnostic clue for progressive myoclonus ataxia, suggesting the presence of genetic disorders.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Subgroup analyses support PrimeC’s potential in ALS treatment, aiming to inform upcoming trials for efficacy.

As the company gains more information about the patient death, dosing in the other phase 3 trial, CIFFREO, has been paused until further notice.

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.

STS101 demonstrated mild and predictable adverse events, suggesting potential efficacy at 5.2 mg dose for migraines.

The FDA AdComm will deliberate over the phase 3 TRAILBLAZER-ALZ 2 trial, a large-scale study that assessed the efficacy and safety of donanemab in patients with early-stage Alzheimer disease over an 18-month period.

The phase 1 open-label, dose-escalation study will include 9 participants with mild-to-moderate Alzheimer disease whose treatment is not addressed adequately by available therapy.

Despite failing to meet the primary end point, AMO-02 achieved clinically and statistically significant benefit in various functional and objective assessments in the phase 2/3 REACH-CDM trial.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how Apple's expected announcement of new iPads with OLED displays could revolutionize cognitive health and dementia care for older adults.

Regarding new-onset seizures in the general population, there was no statistically significant difference in risk of seizure incidence among vaccinated individuals vs placebo recipients, according to the meta-analysis.

Here's some of what is coming soon to NeurologyLive® this week.

A recent case series showed concerning trends of neurological conditions from mosquito-borne diseases impacting patients living in Canada and the United States.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on treatment-refractory epilepsy.

To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.

ASPIRO, an open-label trial, will assess the safety and tolerability of ANPD001, an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 3, 2024.

Recent preclinical findings revealed SBT-589's potential to treat cardiomyopathy in Friedreich ataxia by targeting mitochondrial dysfunction.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Justin Klee and Josh Cohen. [LISTEN TIME: 19 minutes]

Leslie Citrome, MD, MPH, clinical professor of psychiatry and behavioral sciences at New York Medical College, shared his reaction to the recently approved new sprinkle formulation of valbenazine for patients with tardive dyskinesia.